Direct vasoprotection by aspirin: A significant bonus to antiplatelet activity?

Cardiovascular Research

Volumn 64, Issue 2, 2004, Pages 192-194

  Kojda, Georg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; IBUPROFEN; MATRIX METALLOPROTEINASE;

ACETYLATION; CARDIOVASCULAR RISK; CATALYSIS; CLINICAL TRIAL; EDITORIAL; ENZYME ACTIVITY; HUMAN; ISCHEMIC HEART DISEASE; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ASPIRIN; CORONARY DISEASE; CYCLOOXYGENASE INHIBITORS; DEPRESSION, CHEMICAL; ENDOTHELIUM, VASCULAR; HUMANS; MATRIX METALLOPROTEINASE 1; OXIDATIVE STRESS; RECEPTORS, LDL; RECEPTORS, OXIDIZED LDL; SCAVENGER RECEPTORS, CLASS E;

EID: 5444235706     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.07.008     Document Type: Editorial

References (25)

1. Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group N. Engl. J. Med. 321 1989 129 135
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 8607 1988 349 360
3. Anonymous Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
4. E. Braunwald Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction Circulation 108 2003 III28 III37
5. K. Schror Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis Semin. Thromb. Hemost. 23 1997 349 356
6. EUROASPIRE II Study Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme Eur. Heart J. 22 2001 554 572
7. D.L. DeWitt, and W.L. Smith Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence Proc. Natl. Acad. Sci. U. S. A. 85 1988 1412 1416
8. F. Catella-Lawson, M.P. Reilly, and S.C. Kapoor Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N. Engl. J. Med. 345 2001 1809 1817
9. G. Kojda, and D.G. Harrison Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure Cardiovasc. Res. 43 1999 562 571
10. M. Reilly, N. Delanty, J.A. Lawson, and G.A. FitzGerald Modulation of oxidant stress in vivo in chronic cigarette smokers Circulation 94 1996 19 25
11. S. Oberle, T. Polte, A. Abate, H.P. Podhaisky, and H. Schroder Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway Circ. Res. 82 1998 1016 1020
12. J.P. Noon, B.R. Walker, M.F. Hand, and D.J. Webb Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin Cardiovasc. Res. 38 1998 480 484
13. R. Wu, D. Lamontagne, and J. de Champlain Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats Circulation 105 2002 387 392
14. J.L. Mehta, J. Chen, F. Yu, and D.Y. Li Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells Cardiovasc. Res. 64 2004 243 249
15. B. Dahlen, L.O. Boreus, P. Anderson, R. Andersson, and O. Zetterstrom Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects Allergy 49 1994 43 49
16. M.A. Saunders, L. Sansores-Garcia, D.W. Gilroy, and K.K. Wu Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts J. Biol. Chem. 276 2001 18897 18904
17. M. Yuan, N. Konstantopoulos, and J. Lee Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta Science 293 2001 1673 1677
18. L. Vergnani, S. Hatrik, and F. Ricci Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability Circulation 101 2000 1261 1266
19. U. Rueckschloss, J. Galle, J. Holtz, H.R. Zerkowski, and H. Morawietz Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy Circulation 104 2001 1767 1772
20. M.T. Gewaltig, and G. Kojda Vasoprotection by nitric oxide: mechanisms and therapeutic potential Cardiovasc. Res. 55 2002 250 260
21. N. Grosser, and H. Schroder Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway Arterioscler. Thromb. Vasc. Biol. 23 2003 1345 1351
22. K. Prasad, and P. Lee Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin J. Cardiovas. Pharmacol. Ther. 8 2003 61 69
23. T. Cyrus, S. Sung, L. Zhao, C.D. Funk, S. Tang, and D. Pratico Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice Circulation 106 2002 1282 1287
24. M.J. Smith, K.G. Allen, J.F. Norman, M.A. Harris, and C.W. Miller Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin Prostaglandins, Leukot. Essent. Fat. Acids 53 1995 331 340
25. C. Napoli, G. Cirino, and P. Del Soldato Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice Proc. Natl. Acad. Sci. U. S. A. 98 2001 2860 2864